{"corpus_id":7488532,"paper_sha":"d21d2fc3836166ca4884607bd0fb28ad09c5bfa1","doi":"10.1001/JAMA.297.17.1883","arxiv_id":null,"pmid":17473298,"pmcid":null,"mag_id":2187792525,"dblp_id":null,"acl_id":null,"title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.","year":2007,"publication_date":"2007-05-02","venue":"Journal of the American Medical Association (JAMA)","journal":{"name":"JAMA","pages":"\n          1883-91\n        ","volume":"297 17"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Comparative Study","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":37,"citation_count":1006,"influential_citation_count":31,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Acute Disease","mj":false,"ui":"D000208"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Cardiotonic Agents","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D002316"},{"d":"Dobutamine","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D004280"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Heart Failure","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"},{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D006333"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Hydrazones","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D006835"},{"d":"Infusions, Intravenous","mj":false,"ui":"D007262"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Natriuretic Peptide, Brain","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D020097"},{"d":"Pyridazines","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D011724"},{"d":"Simendan","mj":false,"ui":"D000077464"},{"d":"Survival Analysis","mj":false,"ui":"D016019"}],"chemicals":[{"n":"Cardiotonic Agents","ui":"D002316","reg":"0"},{"n":"Hydrazones","ui":"D006835","reg":"0"},{"n":"Pyridazines","ui":"D011724","reg":"0"},{"n":"Natriuretic Peptide, Brain","ui":"D020097","reg":"114471-18-0"},{"n":"Simendan","ui":"D000077464","reg":"349552KRHK"},{"n":"Dobutamine","ui":"D004280","reg":"3S12J47372"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://jamanetwork.com/journals/jama/articlepdf/206883/joc70043_1883_1891.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/d21d2fc3836166ca4884607bd0fb28ad09c5bfa1","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"CONTEXT: Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival. OBJECTIVE: To assess the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival. DESIGN, SETTING, AND PATIENTS: The Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. INTERVENTIONS: Intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663). MAIN OUTCOME MEASURE: All-cause mortality at 180 days. RESULTS: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group (P<.001 for all time points). There were no statistical differences between treatment groups for the other secondary end points (all-cause mortality at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea at 24 hours, and cardiovascular mortality at 180 days). There was a higher incidence of cardiac failure in the dobutamine group. There were higher incidences of atrial fibrillation, hypokalemia, and headache in the levosimendan group. CONCLUSION: Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00348504.","claims":[{"public_id":"cl_f16545c61e56d651a76a28dc497dcc6e","status":"active","text":"All-cause mortality at 180 days occurred in 173 patients in the levosimendan group and 185 patients in the dobutamine group, corresponding to a hazard ratio of 0.91 with a 95% confidence interval of 0.74-1.13.","confidence":0.97,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_f16545c61e56d651a76a28dc497dcc6e"},{"public_id":"cl_f7551298dcc1479f54dea30c57aaca95","status":"active","text":"Cardiac failure was reported more often in the dobutamine group, while atrial fibrillation, hypokalemia, and headache were reported more often in the levosimendan group.","confidence":0.95,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_f7551298dcc1479f54dea30c57aaca95"},{"public_id":"cl_068d3dcc684dffbaa3a2b2c75b91f09b","status":"active","text":"Intravenous levosimendan did not significantly reduce all-cause mortality at 180 days compared with intravenous dobutamine in patients hospitalized with acute decompensated heart failure who required inotropic support.","confidence":0.98,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_068d3dcc684dffbaa3a2b2c75b91f09b"},{"public_id":"cl_80c3b3ceaee1a7cd7a98a2511113aef1","status":"active","text":"The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group.","confidence":0.96,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_80c3b3ceaee1a7cd7a98a2511113aef1"},{"public_id":"cl_df4afcd0cf7d7d051f6462233a96db2a","status":"active","text":"There were no statistical differences between treatment groups for secondary clinical end points including all-cause mortality at 31 days, days alive and out of the hospital, patient global assessment, dyspnea at 24 hours, and cardiovascular mortality at 180 days.","confidence":0.95,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_df4afcd0cf7d7d051f6462233a96db2a"}],"concepts":[{"public_id":"co_03c14b79287d32c693db2c5ec5abaffd","status":"active","name":"hazard ratio","description":"A comparative survival measure reported for all-cause mortality between the treatment groups.","types":["statistical measure"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_03c14b79287d32c693db2c5ec5abaffd"},{"public_id":"co_11cf6a878a29164ab03ad96f61db8e1d","status":"active","name":"levosimendan group","description":"The randomized group of 664 patients assigned to receive intravenous levosimendan.","types":["study group"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_11cf6a878a29164ab03ad96f61db8e1d"},{"public_id":"co_1a171ee9d46b67ff519ca27fe25b4c68","status":"active","name":"B-type natriuretic peptide level","description":"A plasma biomarker level measured over time after treatment in the trial.","types":["biomarker"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_1a171ee9d46b67ff519ca27fe25b4c68"},{"public_id":"co_1b526db7f0b97088f94ceb3220c00f02","status":"active","name":"cardiovascular mortality at 180 days","description":"A secondary outcome tracking deaths attributed to cardiovascular causes by 180 days.","types":["outcome measure"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_1b526db7f0b97088f94ceb3220c00f02"},{"public_id":"co_31ca8930553df85b66f82b0d7ab408cc","status":"active","name":"secondary clinical outcomes","description":"Additional clinical end points assessed beyond the main 180-day mortality outcome.","types":["outcome measure"],"aliases":["secondary end points"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_31ca8930553df85b66f82b0d7ab408cc"},{"public_id":"co_4ae3a3ad2fd187b2e47335c3b92618ed","status":"active","name":"dobutamine group","description":"The randomized group of 663 patients assigned to receive intravenous dobutamine.","types":["study group"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_4ae3a3ad2fd187b2e47335c3b92618ed"},{"public_id":"co_510ceb20102ca1ad6c6925b8ea21a9af","status":"active","name":"intravenous levosimendan","description":"A short-term intravenous inotropic treatment evaluated in the trial.","types":["intervention"],"aliases":["levosimendan"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_510ceb20102ca1ad6c6925b8ea21a9af"},{"public_id":"co_51536303bae0620e186a7f853e25c699","status":"active","name":"intravenous dobutamine","description":"A short-term intravenous inotropic treatment used as the comparator in the trial.","types":["intervention"],"aliases":["dobutamine"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_51536303bae0620e186a7f853e25c699"},{"public_id":"co_7ef0c670a42c06251ece721ec7f48ba4","status":"active","name":"atrial fibrillation","description":"A cardiac rhythm adverse event reported in the safety comparison.","types":["adverse event"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_7ef0c670a42c06251ece721ec7f48ba4"},{"public_id":"co_8711d0b3288e0e39500ce17d107d3d81","status":"active","name":"acute decompensated heart failure","description":"A hospitalization condition in which patients had worsening heart failure requiring intravenous inotropic support.","types":["condition"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_8711d0b3288e0e39500ce17d107d3d81"},{"public_id":"co_adb43147c3367c5ae3d5cb29aa854732","status":"active","name":"all-cause mortality at 180 days","description":"The main outcome measure tracking death from any cause 180 days after treatment assignment.","types":["outcome measure"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_adb43147c3367c5ae3d5cb29aa854732"},{"public_id":"co_bfc4366a968a1a4506bf27d45b487b6f","status":"active","name":"cardiac failure","description":"An adverse event category reported with different incidence between treatment groups.","types":["adverse event"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_bfc4366a968a1a4506bf27d45b487b6f"},{"public_id":"co_d69bbb3142340fadb6aeda4887da39e7","status":"active","name":"patient assessment of dyspnea at 24 hours","description":"A secondary patient-reported outcome measuring shortness of breath 24 hours after treatment.","types":["outcome measure"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_d69bbb3142340fadb6aeda4887da39e7"},{"public_id":"co_dd67b17ee215e3211e69938356b37937","status":"active","name":"hypokalemia","description":"A low-potassium adverse event reported in the safety comparison.","types":["adverse event"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_dd67b17ee215e3211e69938356b37937"}],"external_ids":{"DOI":"10.1001/JAMA.297.17.1883","ArXiv":null,"PubMed":17473298,"PubMedCentral":null,"MAG":2187792525,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://jamanetwork.com/journals/jama/articlepdf/206883/joc70043_1883_1891.pdf","landing_url":"https://www.semanticscholar.org/paper/d21d2fc3836166ca4884607bd0fb28ad09c5bfa1","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632245,"paper_uid":"17bd31d2-149a-46de-9283-e097787ef72f","canonical_identity":{"paper_id":632245,"paper_uid":"17bd31d2-149a-46de-9283-e097787ef72f","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/7488532"}